SpectraScience Optical Biopsy
This article was originally published in The Gray Sheet
Modular PMA is filed with FDA for detection of colorectal cancer. Intended to expedite the standard PMA review process, the modular process "should enable us to achieve our goal of obtaining FDA clearance to market in the first quarter of 1999," SpectraScience says
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.